SCHEMBL4284112

SCHEMBL4284112

C=C1CCCCC1n1cnc(C(=O)OCC)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
CYP19A1 P11511 3/20 0.42
TSHR P16473 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ELANE P08246 1/20 0.40
NPSR1 Q6W5P4 3/20 0.40
MAPT P10636 3/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4283856 0.89 GABRA1 (0.46) ALDH1A1CYP3A4CYP2C9CYP2C19GABRA1
SCHEMBL13705530 0.89 ALDH1A1 (0.40) ALDH1A1CYP3A4CYP2C9CYP2C19MEN1
SCHEMBL13819262 0.85 CYP11B2 (0.39) MEN1KMT2AGAAHSD17B10
SCHEMBL3494838 0.82 GABRA1 (0.44) ALDH1A1CYP3A4CYP2C9CYP2C19GABRA1
SCHEMBL4282668 0.81 CYP19A1 (0.45) ALDH1A1CYP3A4CYP2C9CYP2C19GABRA1
SCHEMBL4282660 0.81 CYP19A1 (0.45) ALDH1A1CYP3A4CYP2C9CYP2C19GABRA1
SCHEMBL8113044 0.81 CYP19A1 (0.45) ALDH1A1CYP3A4CYP2C9CYP2C19GABRA1
SCHEMBL4282663 0.81 CYP19A1 (0.45) ALDH1A1CYP3A4CYP2C9CYP2C19GABRA1
SCHEMBL4281594 0.81 CYP19A1 (0.45) ALDH1A1CYP3A4CYP2C9CYP2C19GABRA1
SCHEMBL4296722 0.81 CYP19A1 (0.45) ALDH1A1CYP3A4CYP2C9CYP2C19GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT ALDH1A1 388/4885CYP3A4 50/4885CYP2C9 40/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT ALDH1A1 388/4885CYP3A4 50/4885CYP2C9 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.